|
|
Volumn 11, Issue 8, 2015, Pages 443-
|
|
First-in-human phase i trial of DC immunotherapy for early RA
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE;
ANTIRHEUMATIC AGENT;
AUTOANTIGEN;
CYCLIC CITRULLINATED PEPTIDE ANTIBODY;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
HLA DRB1 ANTIGEN;
INTERLEUKIN 4;
RHEUMAVAX;
UNCLASSIFIED DRUG;
CITRULLINE;
HLA ANTIGEN;
PEPTIDE;
ANTIBODY SPECIFICITY;
ANTIGEN PRESENTATION;
ANTIGEN SPECIFICITY;
BIOLOGICAL ACTIVITY;
CONTROLLED CLINICAL TRIAL (TOPIC);
DENDRITIC CELL;
DRUG TOLERABILITY;
HUMAN;
IMMUNE RESPONSE;
IMMUNOMODULATION;
IMMUNOTHERAPY;
LYMPHOCYTE COUNT;
NONHUMAN;
NOTE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SAFETY;
T LYMPHOCYTE;
TREATMENT RESPONSE;
UNSPECIFIED SIDE EFFECT;
ARTHRITIS, RHEUMATOID;
CHEMISTRY;
FEMALE;
GENETICS;
IMMUNOLOGY;
MALE;
ARTHRITIS, RHEUMATOID;
CITRULLINE;
DENDRITIC CELLS;
FEMALE;
HLA ANTIGENS;
HUMANS;
IMMUNOTHERAPY;
MALE;
PEPTIDES;
|
|
EID: 84938421580
PISSN: 17594790
EISSN: 17594804
Source Type: Journal
DOI: 10.1038/nrrheum.2015.90 Document Type: Note |
|
Times cited : (6)
|
|
References (1)
|
